Plasmid

Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme

Retrieved on: 
Thursday, August 24, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, DNA, Human, Plasmid, GBM, Neuro-Oncology (journal), MGMT, Immunome, Glioblastoma, Brain, Dana–Farber Cancer Institute, Patient, Therapy, Safety, Pharmaceutical industry

Immunomic Therapeutics, Inc., a privately held, clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced dosing of the first patient in its Phase 1 clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer.

Key Points: 
  • Immunomic Therapeutics, Inc., a privately held, clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced dosing of the first patient in its Phase 1 clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer.
  • The study is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts and is being led by Dr. David Reardon, Clinical Director, Center for Neuro-Oncology.
  • "Dosing of the first patient in the Phase 1 clinical trial of ITI-1001 in patients with GBM is a significant clinical development milestone for Immunomic, representing the first time this pDNA vaccine is being administered in humans,” stated Dr. Teri Heiland, Chief Scientific Officer of Immunomic Therapeutics.
  • For more information on the Phase 1 trial of ITI-1001 in GBM, please visit www.clinicaltrials.gov , NCT05698199

AGC Biologics Partners with Asahi Kasei Pharma Corporation on Clinical Antibody Project

Retrieved on: 
Tuesday, August 15, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Messenger RNA, Plasmid, Viral vector, Perfusion, Cell therapy, AGC, History, Messenger, Food and Drug Administration, CDMO, CGMP, FDA, Food, Fine chemical

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new agreement with Asahi Kasei Pharma Corporation to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.

Key Points: 
  • AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new agreement with Asahi Kasei Pharma Corporation to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.
  • Under the agreement, AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process optimization, and clinical manufacturing of the Asahi Kasei Pharma drug substance.
  • “We look forward to partnering with Asahi Kasei Pharma to help achieve their goals with this important project.”
    AGC Biologics runs multiple mammalian cGMP manufacturing lines at various scales at its Seattle facility.
  • To learn more about AGC Biologics’ biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle .

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Communication, De novo, Classification, Nucleotide, UTI, European Patent Office, Infection, Curetis, Thermo Fisher Scientific, AMR, IP, Sale, Nadine Opgen-Rhein, Single-nucleotide polymorphism, Urinary tract infection, Patent, SNP, Medicine, European Patent Convention, Plasmid, IVD, FDA, Ares, Pneumonia, Video game, Pharmaceutical industry, Q2

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results.
  • Second Quarter 2023 and First Half 2023 Financial Results of OpGen, Inc.
    Total revenue for the second quarter of 2023 was approximately $0.7 million compared to the company’s revenue of approximately $1.0 million in the second quarter of 2022, which was primarily driven by the one-time sale of a pool of Unyvero instrument systems to Menarini in Q2-2022.
  • Total operating expenses decreased in the second quarter of 2023 to approximately $5.9 million compared to approximately $6.2 million for the second quarter of 2022.
  • ET, to review the second quarter 2023 financial results and business activities, but will not be taking any questions.

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Online, GMP, Bevacizumab, Virus, Temperature, Investigational New Drug, Cell, Investment, Therapeutic vaccines, Chemistry, Immunoglobulin G, Development, Private law, R, News, BIO, Good manufacturing practice, Vaccination, Silicon Valley Bank, Mpox, CGMP, Mass, Manuscript, Break, FDA, Earnings call, Vaccine, Death, IND, Safety, Canada, DNA, Plasmid, AACR, COVID-19, American Association for Cancer Research, Immunotherapy, Messenger, Anwar (name), Silicon, Mortality, Research, Response, BioRxiv, Hospital, SARS-CoV-2, CMC, EDT, Sale, Model, CDMO, Mouse, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, Security (finance), Conference, Biotechnology

LAWRENCEVILLE, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced financial results for the three and six months ended June 30, 2023. The Company also provided an update on its clinical development programs with IMNN-001 (formerly GEN-1), a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic non-viral and synthetic DNA technology for the expression of pathogen antigens, being evaluated in preclinical studies for the development of next-generation vaccines.

Key Points: 
  • Operating expenses were $5.5 million for the second quarter of 2023, a decrease of $0.6 million, or 10%, from $6.1 million for the second quarter of 2022.
  • Other clinical and regulatory costs were $0.4 million for the second quarter of 2023 compared with $0.7 million for the second quarter of 2022.
  • The Company is hosting a conference call to provide a business update, discuss second quarter 2023 financial results and answer questions at 11:00 a.m. EDT today.
  • To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON Second Quarter 2023 Earnings Call.

AGC Biologics Completes Expansion at Milan Cell and Gene Therapy Development and Manufacturing Site

Retrieved on: 
Wednesday, August 9, 2023
Biotechnology, Pharmaceutical, Health, Messenger RNA, GMP, DNA, Plasmid, Gene, Center for Cell and Gene Therapy, Viral vector, Gene-centered view of evolution, AGC, Messenger, CDMO, CGMP, Cell, Heidelberg, Vaccine

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.

Key Points: 
  • AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.
  • “This is another important milestone for our site and for the AGC Biologics global Cell and Gene network as we prepare to serve more developers,” said Luca Alberici, General Manager, AGC Biologics Milan.
  • AGC Biologics operates two cell and gene facilities within its global network, one in Milan and one in Longmont, Col, USA.
  • At each site AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing, and quality/regulatory services, using the latest technology platforms and scientific methods.

OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

Retrieved on: 
Monday, August 7, 2023
Informatics, SOCS2, Infection, Genomics, AMR, Nadine Opgen-Rhein, Houston, Laboratory, SNP, Medicine, Plasmid, WGS, Health, Ares, HIPAA, Vaccine, Antibiotics, Q3

Working with its customers globally, the Ares team has developed the new AREScloud features to provide relevant reporting for hospital epidemiologists and infection preventionists.

Key Points: 
  • Working with its customers globally, the Ares team has developed the new AREScloud features to provide relevant reporting for hospital epidemiologists and infection preventionists.
  • The new AREScloud features are now deployed as part of the standard analysis package, and in use with our customers globally.
  • The new features further broaden the capabilities of AREScloud for microbial genomics that include antimicrobial resistance profiling, and genomic antibiotic sensitivity testing.
  • To support this goal, we continue to enhance our AREScloud features, while making pathogen sequencing both affordable and broadly available.”

Recent Cash Injection Boosts VectorBuilder to Unicorn Status

Retrieved on: 
Wednesday, July 26, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Therapy, SF, Medicine, DSM-IV codes, Cell, AAV, Messenger, Lentivirus, CDMO, CGMP, Series, Plasmid, Legend Holdings, Safety, Pharmaceutical industry, Vaccine

The latest cash injection builds on the $57 million Series C funding completed in November last year, which brings the total amount raised to date to just over $76 million and propels the organization to unicorn status with over $1 billion valuation.

Key Points: 
  • The latest cash injection builds on the $57 million Series C funding completed in November last year, which brings the total amount raised to date to just over $76 million and propels the organization to unicorn status with over $1 billion valuation.
  • VectorBuilder’s new Campus is primed to amplify its R&D and production capacity for both research-use and cGMP-grade gene delivery vectors.
  • “With Dr. Lahn's expertise and an innovative gene delivery service platform, VectorBuilder is serving thousands of top biopharmaceutical companies and research institutes.
  • With clients in over 90 countries and counting, VectorBuilder aims to give access to its’ innovative gene delivery technologies to labs across the world.

CoJourney Inc. Secures $30 Million Financing and Announces Expansion of US Operations: High Quality, Cost Effective, Commercial Scale Manufacturing Platform for Cell and Gene Therapies

Retrieved on: 
Thursday, July 13, 2023
Biotechnology, FDA, Health, Manufacturing, Pharmaceutical, Other Science, Research, General Health, Hospitals, Genetics, Health Technology, Science, Other Manufacturing, Clinical Trials, Legend Holdings, Clinical trial, Messenger, CDMO, Investigational New Drug, CGMP, Plasmid, IND, Vaccine

CoJourney Inc. a global innovator in manufacturing and development of cell and gene therapies is pleased to announce completion of a $30 M Series A financing and expansion of its US organization and commercial manufacturing capabilities.

Key Points: 
  • CoJourney Inc. a global innovator in manufacturing and development of cell and gene therapies is pleased to announce completion of a $30 M Series A financing and expansion of its US organization and commercial manufacturing capabilities.
  • This funding round was led by Legend Holdings and supported by GL Ventures, Legend Star Investment Management and Lake Bleu Capital.
  • CoJourney has developed high efficiency processes to support end-to-end custom development and manufacturing for genetic medicines, including plasmids, viral vectors, and mRNA.
  • The company has built 130,000 square foot state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids.

IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus

Retrieved on: 
Tuesday, June 27, 2023
GMP, DNA, Bevacizumab, Plasmid, Good manufacturing practice, Infection, Research, Cancer, CDMO, CGMP, R, Break, FDA, Ovarian cancer, News, Vaccine, Biotechnology

HUNTSVILLE, Ala., June 27, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, today unveiled its new current Good Manufacturing Practices (cGMP) clinical materials production facility, located on the Huntsville campus of the HudsonAlpha Institute for Biotechnology. The facility is intended to provide IMUNON with additional control over the quantities and costs of manufacturing non-viral DNA-based materials used in its research and development (R&D) activities.

Key Points: 
  • The facility is intended to provide IMUNON with additional control over the quantities and costs of manufacturing non-viral DNA-based materials used in its research and development (R&D) activities.
  • We are proud to reach this important production capability milestone, building on the expansive research campus of HudsonAlpha Institute.
  • IMUNON’s team has extensive experience manufacturing DNA medicines, which is very attractive for current and potential partners.
  • Since the Institute opened in 2008, the IMUNON team has been a valuable part of the HudsonAlpha ecosystem.

GenScript Debuts AmMag™ Quatro to Revolutionize Automated Plasmid Maxi-Prep Purification

Retrieved on: 
Tuesday, June 20, 2023
DNA, Plasmid, Genetic engineering, Workflow, Quatro, Biotechnology, GenScript Biotech, Research, Transfection, Laboratory, Risk, Bacteria, Cell engineering, Vaccine

PISCATAWAY, N.J., June 20, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has added the AmMag™ Quatro automated plasmid purification system to its lab and research product line-up. The system streamlines maxi-scale plasmid purification and reduces the manpower and time needed to purify high-quality, transfection-grade plasmid. Since its introduction, AmMag Quatro has been used at the forefront of biotech research, including breakthrough projects such as viral vector development for cell engineering and gene therapy.

Key Points: 
  • PISCATAWAY, N.J., June 20, 2023 /PRNewswire/ -- GenScript Biotech Corporation , the world's leading provider of life-science research tools and services, has added the AmMag™ Quatro automated plasmid purification system to its lab and research product line-up.
  • The system streamlines maxi-scale plasmid purification and reduces the manpower and time needed to purify high-quality, transfection-grade plasmid.
  • However, traditional plasmid purification methods are highly labor-intensive, inefficient, and prone to costly human or process errors.
  • It has exceeded our expectations in terms of time and cost savings, and it has become the standard for our organization's plasmid purification needs."